약학회지
YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 9.

Table. 9.

The production in facilities of recombinant pharmaceuticals using animal cell culture technology in Korea (2020)

Company name Production capacity Remarks
Korea Samsung Biologics 360,000L Plant 1, 2, 3 (Construction plan for plant 4)
Celltrion 190,000L Plant 1, 2 (Construction plan for plant 3)
Binex 10,700L Acquisition of Hanwha chemical production facility
Dong-A socio 7,500L DM Bio
LG chemical 3,000L
Prestige Biologics 2,000L Plant 1 (Construction plan for plant 2 (20,000L) in Osong)
Osong Biomedical Innovation Foundation 1,500L Biopharmaceutical production center
Eubiologics 700L
AProgen 2.5Ton (as drug substance) Completed in April, 2018
Polus Plant construction in process

Reference Ronza 300,000L Switzerland
Boehringer Ingelheim 265,000L Germany

Yakhak Hoeji 2021;65:1-9 https://doi.org/10.17480/psk.2021.65.1.1
© 2021 Yakhak Hoeji